H.C. Wainwright raised the firm’s price target on Immix Biopharma (IMMX) to $12 from $8 and keeps a Buy rating on the shares as the firm sees increased probability of approval for NXC-201 after Immix presented Phase 2 results from the NEXICART-2 trial at the annual ASH meeting.
Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on IMMX: